RT Journal Article
SR Electronic
T1 SIOP Ependymoma I: Final results, long term follow-up and molecular analysis of the trial cohort: A BIOMECA Consortium Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.29.21261962
DO 10.1101/2021.08.29.21261962
A1 Ritzmann, Timothy A
A1 Chapman, Rebecca J
A1 Kilday, John-Paul
A1 Thorp, Nicola
A1 Modena, Piergiorgio
A1 Dineen, Robert A
A1 Macarthur, Donald
A1 Mallucci, Conor
A1 Jaspan, Timothy
A1 Pajtler, Kristian W
A1 Giagnacovo, Marzia
A1 Jacques, Thomas S
A1 Paine, Simon ML
A1 Ellison, David W
A1 Bouffet, Eric
A1 Grundy, Richard G
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/08/31/2021.08.29.21261962.abstract
AB Background SIOP Ependymoma I was a non-randomised trial assessing event free and overall survival (EFS/OS) from non-metastatic intracranial ependymoma in children aged 3 to 21 years, treated with a staged management strategy. Chemotherapy efficacy in ependymoma is debated and therefore the response rate (RR) of subtotally resected (STR) ependymoma to vincristine, etoposide and cyclophosphamide (VEC) was an additional primary outcome. We report final results with 12-year follow-up and post hoc analyses of recently described biomarkers.Methods 74 participants were eligible. Children with gross total resection (GTR) received radiotherapy, whilst those with STR received VEC before radiotherapy. DNA methylation and 1q status were evaluated, alongside hTERT, ReLA, Tenascin-C, H3K27me3 and pAKT expression.Results Five- and ten-year EFS was 49.5% and 46.7%, OS was 69.3% and 60.5%. GTR was achieved in 33/74 (44.6%) and associated with improved EFS (p=0.003, HR=2.6, 95% confidence interval (CI) 1.4-5.1). Grade 3 tumours were associated with worse OS (p=0.005, HR=2.8, 95%CI 1.3-5.8). 1q gain and hTERT expression were associated with poorer EFS (p=0.003, HR=2.70, 95%CI 1.49-6.10 and p=0.014, HR=5.8, 95%CI 1.2-28 respectively) and H3K27me3 loss with worse OS (p=0.003, HR=4.6, 95%CI 1.5-13.2). DNA methylation profiles showed expected patterns. 12 participants with STR did not receive chemotherapy; a protocol violation. However, chemotherapy RR was 65.5% (19/29, 95%CI 45.7-82.1), exceeding a prespecified 45% RR.Conclusions RR of STR to VEC exceeded the pre-specified criterion for efficacy. However, cases of inaccurate treatment stratification highlighted the need for rapid central review. Prognostic associations for 1q gain, H3K27me3 and hTERT were confirmed.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT00004224Funding StatementThe study was supported by CRUK Childrens Cancer Trials Team at the University of Birmingham and we acknowledge Andrew Raxworthy-Cooper for his support. TAR is an NIHR Academic Clinical Lecturer. TAR and RG received funding from the James Tudor Foundation and Fighting Ependymoma. TSJ received funding from the Brain Tumour Charity Children with Cancer UK Great Ormond Street Hospital Childrens Charity Olivia Hodson Cancer Fund Cancer Research UK and the NIHR. Research at GOSH and UCL Great Ormond Street Institute of Child Health is made possible by the NIHR GOSH Biomedical Research Centre. PM and MG received funding from Associazione Bianca Garavaglia.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was given ethical approval by the Trent Multicentre Research Ethics Committee (MREC - UK ethical approval) (MREC99/02/11. CTA reference MF8000/13710). The trial was approved by the UK Childrens Cancer Study Group (CSSG) and SIOP. Participants were monitored though the Childrens Cancer and Leukaemia Group (CCLG) data centre. The clinicaltrials.gov identifier was NCT00004224.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is related to individual patients but anonymised data can be provided by the authors following a reasonable request. DNA methylation profile data has been deposited for public access at the gene expression omnibus: GSE182707.